Welcome!

News Feed Item

Analysis of the Global Biosimilars Market

NEW YORK, Jan. 28, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Analysis of the Global Biosimilars Market

http://www.reportlinker.com/p01979537/Analysis-of-the-Global-Biosimilars-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Impending Patent Expiries and Next-generation Biosimilars Pipeline Provide Impetus for Growth

Patent expirations of blockbuster biologics and a promising pipeline of biosimilars present positive opportunities for the global market. The research service provides analysis on regional market penetration and market dynamics. This study also provides a market overview, market engineering measurements, revenue forecasts, competitive analysis, and key trends for the biosimilars market and its segments. Regional analysis includes The United States, European countries such as the United Kingdom, Germany, France, Italy, Spain, Benelux, and Scandinavia as well as Asia-Pacific and Latin America. The study period is 2009–2019, with 2012 as the base year.

Methodology

•The information contained in this research service was derived from a variety of relevant primary and secondary information sources.
•Primary interviews were conducted with industry participants in positions such as chairman and chief executive officer (CEO), director of investor relations, director of business development, chief business officer, media relations, and international key opinion leaders (KOL).
•Secondary data sources include government and public health organisation websites, the World Health Organization (WHO), European Medicines Agency (EMA), the US Food and Drug Administration (FDA) publications (annual reports, US Securities and Exchange Commission (SEC) filings, investor presentations, earnings transcripts, and press releases), government public sources, pharmaceutical industry databases, and published articles in scientific and medical journals.
•For the United States, Europe, and Latin America (LATAM), revenue forecasting is performed using a robust, data-driven, bottom-up approach. Marketed drugs, patent expiries, and potential new entrants in phase 3 of development and beyond are individually forecasted, and aggregate figures are provided. For the Asia-Pacific (APAC) region, forecasting is performed using a top-down model.

Key Findings

•The global biosimilars market will continue to grow from $X million in 2012 to approximately $X million in 2019, at a compound annual growth rate (CAGR) of X%.
•The biosimilars market is a growth market. The period from 2013 to 2015 is considered a time of significance for higher growth, with new products and segments adding up during this time period. Regulatory guidelines have been drafted by the EMA for erythropoietins (EPO), granulocyte colony stimulating factors (G-CSF), human growth hormone (HGH), and monoclonal antibodies (mAbs). The United States, India, and other regions have also drafted guidelines as the pathways are gradually becoming clear.
•The European market seems favourable due to increasing pressure to control the spiralling costs of healthcare. Biosimilar mAbs are thus expected to experience a positive trend in the region.
•The US market is underpenetrated, and a huge opportunity awaits biosimilar manufacturers.
•The Russian government plans to promote the country's domestic biosimilars industry through subsidies and contracts for companies actively developing biosimilars.
•Several regional governments are actively promoting the growth of biosimilars. For example, the South Korean government is striving to make its country a global market leader, with the goal of attaining a global market share of X% by 2020 and with provisions of both financial and institutional support for those involved.
•Partnerships and alliances are the major focus of firms entering the biosimilars market, and there have been some notable deals between generic participants and biotech firms. Examples include generics giant Teva and a biologicals firm Cephalon, Indian generics manufacturer Lupin Pharmaceuticals and Australian biotech Neuclone, and German STADA Arzneimittel's mAbs deal with Hungary-based Gedeon Richter.
•Non-pharma participants have made their entry into biosimilars through partnerships. For example, Japanese digital camera maker Fujifilm is developing biosimilars with the biotech firm Kyowa Hakko Kirin, and Korean electronics giant Samsung struck biosimilar deals with contract research organisation (CRO) Quintiles and, more recently, with the US biotech Biogen Idec.

Scope and Segmentation

Geographic Coverage: Global
Study Period: 2009–2019
Base Year: 2012
Forecast Period: 2013–2019
Monetary Unit: US Dollars

This report covers the following geographic markets:
•The United States
•European countries such as the United Kingdom, Germany, France, Italy, and Spain
oThe Benelux region: Belgium, Netherlands, and Luxembourg
oThe Scandinavian region: Denmark, Norway, and Sweden
•APAC: India, China, South Korea, Japan, and Australia
•LATAM: Brazil, Mexico, and Argentina

Key Questions This Study Will Answer

What is the current scenario of the global biosimilars market, and how far will it go?
What are the key factors driving the market, and what are the barriers that need to be resolved?
Which are the key market segments to look out for, and what are the key trends and regulatory aspects?
Who are the key market participants involved, and where do they stand?
What are the factors affecting the biosimilars market in different regions of Europe, and how will these factors affect the market in the future?
What is the future biosimilars market scenario, and what should market participants do to succeed?

Table of Contents

1. Executive Summary
• Key Findings
• Scope and Segmentation
• Key Questions This Study Will Answer
• Market Engineering Measurements
• CEO's Perspective
• Key Companies to Watch
• Executive Summary—3 Big Predictions
2. Market Overview
• Comparative Analysis: Generics, Biosimilars, and Biologics
• Market Segmentation
• Geographic Perspective
• Timeline of Key Events
• Biosimilar Trends in the Future
3. Competitive Playbook
• New Market Opportunities
• Merger, Acquisition, and Partnership Assessment
4. Drivers, Restraints, and Trends—Total Biosimilars Market
• Market Drivers
• Market Restraints
• Impact Mapping of Drivers and Restraints
5. Forecasts and Trends—Total Biosimilars Market
• Market Engineering Measurements
• Forecast Assumptions and Definitions
• Revenue Forecast
• Revenue Forecast Discussion
• Percent Revenue Forecast by Region
• Revenue Forecast by Region
• Emerging Trends—Biobetters
6. Competitive Environment
• Competitive Landscape Analysis
• Pipeline Analysis
• Market Share Analysis—Global
7. Key Companies to Watch
• Companies to Watch
8. Europe Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Market Analysis
• Pricing Analysis
• Pricing Trends and Forecast
• PEST Analysis
• Market Share Analysis
• Marketed Product Analysis
• Biologics Patent Expiry Analysis
• Patent Expirations
9. Europe Erythropoietin Segment Breakdown
10. Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
• Regulatory Environment—Europe EPO Biosimilars
11. Europe Granulocyte Colony Stimulating Factors Segment Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
• Regulatory Environment—Europe G-CSF Biosimilars
12. Europe Human Growth Hormone Segment Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
• Regulatory Environment—Europe HGH Biosimilars
13. Europe Insulin Segment Breakdown
• Scenario Revenue Forecast
• Scenario Revenue Forecast Discussion
• Regulatory Environment—Europe Insulin Biosimilars
14. Europe Monoclonal Antibodies Segment Breakdown
• Scenario Revenue Forecast
• Scenario Revenue Forecast Discussion
• Regulatory Environment—Europe mAbs Biosimilars
15. Europe Interferons Segment Breakdown
• Scenario Revenue Forecast
• Scenario Revenue Forecast Discussion
• Regulatory Environment—Europe Interferon Biosimilars
16. The United Kingdom Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
17. Germany Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
18. France Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
19. Italy Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
20. Spain Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
21. Benelux Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
22. Scandinavia Breakdown
• Market Overview
• Market Engineering Measurements
• Revenue Forecast
• Revenue Forecast Discussion
23. The United States Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
• Regulatory Environment
• Pricing Analysis
• PEST Analysis
• Biologics Patent Expiry Analysis
• Patent Expirations
24. The United States Erythropoietin Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Scenario Revenue Forecast
• Scenario Revenue Forecast Discussion
25. The United States Granulocyte Colony Stimulating Factors Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Scenario Revenue Forecast
• Scenario Revenue Forecast Discussion
26. The United States Human Growth Hormone Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Pricing Trends and Forecast
• Pricing Trends and Forecast Discussion
27. The United States Insulin Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Scenario Revenue Forecast
• Scenario Revenue Forecast Discussion
28. The United States Monoclonal Antibodies Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Scenario Revenue Forecast
• Scenario Revenue Forecast Discussion
29. The United States Interferons Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Pricing Trends and Forecast
• Pricing Trends and Forecast Discussion
30. China Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
• PEST Analysis
• Regulatory Environment
• Market Share Analysis
31. China Erythropoietin Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Pricing Analysis
• Local Market Participants
32. China Granulocyte Colony Stimulating Factors Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Pricing Analysis
• Local Market Participants
33. China Human Growth Hormone Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Pricing Analysis
• Local Market Participants
34. China Insulin Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Pricing Analysis
• Local Market Participants
35. China Monoclonal Antibodies Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Local Market Participants
36. China Interferons Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Pricing Analysis
• Local Market Participants
37. India Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
• Regulatory Environment
• PEST Analysis
38. South Korea Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
• Regulatory Environment
• Reimbursement System and Pricing Analysis
• PEST Analysis
• Marketed Product Analysis
• Pipeline Analysis
39. Japan Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
• Regulatory Environment
• Pricing Analysis
• Pricing Trends and Forecast
• PEST Analysis
• Product Analysis
40. Australia Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
• Pricing Analysis
• Pricing Trends and Forecast
• PEST Analysis
41. Latin America Breakdown
• Market Overview—Biosimilars
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
• Regulatory Environment
• Pricing Analysis
• Pricing Trends and Forecast
• Pricing Trends and Forecast Discussion
• PEST Analysis
• Competitive Analysis
42. Latin America Erythropoietin Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
43. Latin America Granulocyte Colony Stimulating Factors Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
44. Latin America Human Growth Hormone Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
45. Latin America Insulin Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
46. Latin America Monoclonal Antibodies Segment Breakdown
• Market Overview
47. Latin America Interferons Segment Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
48. Brazil Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
49. Mexico Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
50. Argentina Breakdown
• Revenue Forecast
• Revenue Forecast Discussion
• Market Analysis
51. The Last Word
• The Last Word—3 Big Predictions
• The Last Word—Discussion
• Legal Disclaimer
52. Appendix
• Market Overview
• Market Definitions
• Market Background
• Drivers Explained
• Restraints Explained
• Market Engineering Methodology
• Learn More—Next Steps
• Decision Support Databases

List of Exhibits

• Total Biosimilars Market: Market Engineering Measurements, Global, 2012
• Comparative Analysis: Generics, Biosimilars, and Biologics, Global, 2012
• Total Biosimilars Market: Market Segmentation, Global, 2012
• Total Biosimilars Market: Percent Revenue by Geographic Region, Global, 2012
• Total Biosimilars Market: Timeline of Key Events, Global, 2012 and 2013
• Total Biosimilars Market: Market Outlook, Global, 2012 and 2022
• Total Biosimilars Market: Game-changing Strategies, Global, 2012
• Total Biosimilars Market: Market Outlook, Global, 2012
• Total Biosimilars Market: Key Market Drivers, Global, 2013–2019
• Total Biosimilars Market: Key Market Restraints, Global, 2013–2019
• Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Global,
2013–2019
• Total Biosimilars Market: Market Engineering Measurements, Global, 2012
• Total Biosimilars Market: Revenue Forecast, Global, 2009–2019
• Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2009–2017
• Total Biosimilars Market: Revenue Forecast by Region, Global, 2009–2019
• Total Biosimilars Market: Competitive Landscape Analysis, Global, 2012
• Total Biosimilars Market: Pipeline Analysis, Global, 2012
• Total Biosimilars Market: Competitive Landscape, Global, 2012
• Total Biosimilars Market: Percent Sales Breakdown, Global, 2012
• Total Biosimilars Market: Company Market Share Analysis of Top 5 Participants, Global, 2012
• Biosimilars Market: Key Stake Holders, Europe, 2012
• Biosimilars Market: Market Engineering Measurements, Europe, 2012
• Biosimilars Market: Revenue Forecast, Europe, 2009–2019
• Biosimilars Market: Pricing Analysis, Europe, 2012
• Biosimilars Market: Time from Marketing Authorisation to Price Approval, Europe, 2012
• Biosimilars Market: Average Price for EPO, Europe, 2009–2019
• Biosimilars Market: Average Price for G-CSF, Europe, 2009–2019
• Biosimilars Market: Average Price for HGH, Europe, 2009–2019
• Biosimilars Market: PEST Analysis, Europe, 2012
• Biosimilars Market: Percent of Sales, Europe, 2012
• Biosimilars Market: Company Market Share Analysis of Top 5 Participants, Europe, 2012
• Biosimilars Market: Ranking of Key Participants Based on Market Share, Europe, 2012
• Biosimilars Market: Competitive Landscape, Europe, 2012
• Biosimilars Market: Marketed Product Analysis, Europe, 2012
• Biologics Market: Patent Expiry Analysis, Europe, 2012
• Biologics Market: Patent Expirations, Europe, 2000–2030
• EPO Segment: Market Engineering Measurements, Europe, 2012
• EPO Segment: Revenue Forecast, Europe, 2009–2019
• G-CSF Segment: Market Engineering Measurements, Europe, 2012
• G-CSF Segment: Revenue Forecast, Europe, 2009–2019
• HGH Segment: Market Engineering Measurements, Europe, 2012
• HGH Market: Revenue Forecast, Europe, 2009–2019
• Insulin Segment: Scenario Revenue Forecast, Europe 2015–2019
• mAbs Segment: Scenario Revenue Forecast, Europe 2015–2019
• Interferons Segment: Scenario Revenue Forecast, Europe 2015–2019
• Biosimilars Market: Market Engineering Measurements, UK, 2012
• Biosimilars Market: Revenue Forecast, UK, 2009–2019
• Biosimilars Market: Market Engineering Measurements, Germany, 2012
• Biosimilars Market: Revenue Forecast, Germany, 2009–2019
• Biosimilars Market: Market Engineering Measurements, France, 2012
• Biosimilars Market: Revenue Forecast, France, 2009–2019
• Biosimilars Market: Market Engineering Measurements, Italy, 2012
• Biosimilars Market: Revenue Forecast, Italy, 2009–2019
• Biosimilars Market: Market Engineering Measurements, Spain, 2012
• Biosimilars Market: Revenue Forecast, Spain, 2009–2019
• Biosimilars Market: Market Engineering Measurements, Benelux, 2012
• Biosimilars Market: Revenue Forecast, Benelux, 2009–2019
• Biosimilars Market: Market Engineering Measurements, Scandinavia, 2012
• Biosimilars Market: Revenue Forecast, Scandinavia, 2009–2019
• Biosimilars Market: Revenue Forecast, US, 2009–2019
• Biosimilars Market: Revenue Forecast Comparison between Branded Biologics and Biosimilars, US, 2009–2019
• Biosimilars Market: Timeline of Biosimilars Regulatory Activity, US, 2012
• Biosimilars Market: Overview of Application Requirements for Biosimilars, US, 2012
• Biosimilars Market: Biosimilars User Fee Act Fee Structure, US, 2012
• Biosimilars Market: Pricing Analysis, US, 2012
• Biosimilars Market: PEST Analysis, US, 2012
• Biologics Market: Patent Expiry Analysis, US, 2012
• Biologics Market: Patent Expirations, US, 2000–2030
• EPO Segment: Revenue Forecast, US, 2009–2019
• EPO Segment: Scenario Revenue Forecast, US, 2009–2019
• EPO Segment: Optimistic Scenario—Revenue Forecast, US, 2015–2019
• EPO Segment: Frost & Sullivan Scenario—Revenue Forecast, US, 2015–2019
• EPO Segment: Conservative Scenario—Revenue Forecast, US, 2015–2019
• G-CSF Segment: Revenue Forecast, US, 2009–2019
• G-CSF Segment: Scenario Revenue Forecast, US, 2009–2019
• G-CSF Segment: Optimistic Scenario—Revenue Forecast, US, 2015–2019
• G-CSF Segment: Frost & Sullivan Scenario—Revenue Forecast, US, 2015–2019
• G-CSF Segment: Conservative Scenario—Revenue Forecast, US, 2015–2019
• HGH Segment: Revenue Forecast, US, 2009–2019
• HGH Segment: Revenue Forecast Comparison Between Branded Biologics and Biosimilars, US, 2009–2019
• HGH Segment: Annual Cost of Therapy, US, 2009–2019
• HGH Segment: ACT Comparison Between Branded Biologics and Biosimilars, US,
• 2009–2019
• Insulin Segment: Revenue Forecast, US, 2009–2019
• Insulin Segment: Scenario Revenue Forecast, US, 2009–2019
• Insulin Segment: Optimistic Scenario—Revenue Forecast, US, 2015–2019
• Insulin Segment: Frost & Sullivan Scenario—Revenue Forecast, US, 2015–2019
• Insulin Segment: Conservative Scenario—Revenue Forecast, US, 2015–2019
• mAbs Segment: Revenue Forecast, US, 2009–2019
• Biosimilars Market: Marketed mAbs at Risk for Biosimilar Competition, US, 2012
• mAbs Segment: Scenario Revenue Forecast, US, 2015–2019
• mAbs Segment: Optimistic Scenario—Revenue Forecast, US, 2015–2019
• mAbs Segment: Frost & Sullivan Scenario—Revenue Forecast, US, 2015–2019
• mAbs Segment: Conservative Scenario—Revenue Forecast, US, 2015–2019
• Interferons Segment: Revenue Forecast, US, 2009–2019
• Interferons Segment: Annual Cost of Therapy, US, 2009–2019
• Interferons Segment: ACT Comparison Between Branded Biologics and Biosimilars, US, 2009–2019
• Biosimilars Market: Revenue Forecast, China, 2009–2019
• Biosimilars Market: PEST Analysis, China,2012
• Biosimilars Market: Percent of Sales, China, 2012
• EPO Segment: Revenue Forecast, China, 2009–2019
• EPO Segment: Pricing Analysis, China, 2012
• G-CSF Segment: Revenue Forecast, China, 2009–2019
• G-CSF Segment: Pricing Analysis, China, 2012
• HGH Segment: Revenue Forecast, China, 2009–2019
• HGH Segment: Pricing Analysis, China, 2012
• Insulin Segment: Revenue Forecast, China, 2009–2019
• Insulin Segment: Pricing Analysis, China, 2012
• mABs Segment: Revenue Forecast, China, 2009–2019
• Interferons Segment: Revenue Forecast, China, 2009–2019
• Interferons Segment: Pricing Analysis, China, 2012
• Biosimilars Market: Revenue Forecast, India, 2009–2019
• Biosimilars Market: PEST Analysis, India, 2012
• Biosimilars Market: Revenue Forecast, South Korea, 2009–2019
• Biosimilars Market: Regulatory Guidelines, South Korea, 2012
• Biosmilar Market: PEST Analysis, South Korea, 2012
• Biosimilars Market: Pipeline Analysis, South Korea, 2012
• Biosimilars Market: Revenue Forecast, Japan, 2009–2019
• Biosimilars Market: Regulatory Guidelines, Japan, 2012
• Biosimilars Market: Pricing Analysis, Japan, 2012
• Biosimilars Market: Average Price for G-CSF, Japan, 2009–2019
• Biosimilars Market: Average Price for EPO, Japan, 2009–2019
• Biosimilars Market: PEST Analysis, Japan, 2012
• Biosimilars Market: Product Analysis, Japan, 2012
• Biosimilars Market: Revenue Forecast, Australia, 2009–2019
• Biosimilars Market: Pricing Analysis, Australia, 2012
• Biosimilars Market: PEST Analysis, Australia, 2012
• Biosimilars Market: Revenue Breakdown by Segment, Latin America, 2012
• Biosimilars Market: Revenue Forecast, Latin America, 2009–2019
• Biosimilars Market: Pricing Analysis, Latin America, 2012
• Biosimilars Market: Average Price for G-CSF, Latin America, 2009–2019
• Biosimilars Market: Average Price for HGH, Latin America, 2009–2019
• Biosimilars Market: Average Price for Insulin, Latin America, 2009–2019
• Biosimilars Market: Average Price for Interferons, Latin America, 2009–2019
• Biosimilars Market: PEST Analysis, Latin America, 2012
• Biosimilars Market: Top Biosimilar Companies by Rank, Latin America, 2012
• EPO Segment: Revenue Forecast, Latin America, 2009–2019
• G-CSF Segment: Revenue Forecast, Latin America, 2009–2019
• HGH Segment: Revenue Forecast, Latin America, 2009–2019
• Insulin Segment: Revenue Forecast, Latin America, 2009–2019
• Interferons Segment: Revenue Forecast, Latin America, 2009–2019
• Biosimilars Market: Revenue Forecast, Brazil, 2009–2019
• Biosimilars Market: Revenue Forecast, Mexico, 2009–2019
• Biosimilars Market: Revenue Forecast, Argentina, 2009–2019
• Total Biosimilars Market: Pharma Industry and Biosimilar Trends Market, Global, 2012
• Pharmaceutical and Biotech Industry: Revenue Forecast, Global, 2009–2019
• Decision Support Database: Total Pharmaceutical Market, Global, 2008–2018
• Decision Support Database: Pharmaceutical R&D Expenditure, Global, 2008–2018
• Decision Support Database: Number of Biotech Companies, Global, 2008–2018
• Decision Support Database: Government R&D Expenditure in Biotechnology, Global, 2008–2018
• Decision Support Database: Venture Capital Investment in Biotech R&D, Global, 2008–2018

To order this report: Analysis of the Global Biosimilars Market
http://www.reportlinker.com/p01979537/Analysis-of-the-Global-Biosimilars-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"Codigm is based on the cloud and we are here to explore marketing opportunities in America. Our mission is to make an ecosystem of the SW environment that anyone can understand, learn, teach, and develop the SW on the cloud," explained Sung Tae Ryu, CEO of Codigm, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
"CA has been doing a lot of things in the area of DevOps. Now we have a complete set of tool sets in order to enable customers to go all the way from planning to development to testing down to release into the operations," explained Aruna Ravichandran, Vice President of Global Marketing and Strategy at CA Technologies, in this SYS-CON.tv interview at DevOps Summit at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.